WO2008133036A1 - Procédé de criblage d'un agent thérapeutique pour un dysfonctionnement tubulaire rénal - Google Patents

Procédé de criblage d'un agent thérapeutique pour un dysfonctionnement tubulaire rénal Download PDF

Info

Publication number
WO2008133036A1
WO2008133036A1 PCT/JP2008/057148 JP2008057148W WO2008133036A1 WO 2008133036 A1 WO2008133036 A1 WO 2008133036A1 JP 2008057148 W JP2008057148 W JP 2008057148W WO 2008133036 A1 WO2008133036 A1 WO 2008133036A1
Authority
WO
WIPO (PCT)
Prior art keywords
screening
renal tubular
compound
therapeutic agent
macrophage
Prior art date
Application number
PCT/JP2008/057148
Other languages
English (en)
Japanese (ja)
Inventor
Michio Ishibashi
Original Assignee
Michio Ishibashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michio Ishibashi filed Critical Michio Ishibashi
Priority to JP2009511777A priority Critical patent/JPWO2008133036A1/ja
Publication of WO2008133036A1 publication Critical patent/WO2008133036A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé pour le criblage d'un composé qui peut empêcher, soulager ou traiter une lésion tubulaire rénale. L'invention concerne spécifiquement un procédé pour le criblage d'un composé qui peut empêcher, soulager ou traiter une lésion tubulaire rénale, qui est caractérisé par l'analyse d'un composé d'intérêt quant à son activité de régulation de l'expression de rBAT induite par le contact entre une cellule mononucléaire de sang périphérique humain ou une lignée cellulaire humaine établie en culture ayant une propriété d'un monocyte humain ou d'un macrophage humain et une substance activant les macrophages.
PCT/JP2008/057148 2007-04-12 2008-04-11 Procédé de criblage d'un agent thérapeutique pour un dysfonctionnement tubulaire rénal WO2008133036A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009511777A JPWO2008133036A1 (ja) 2007-04-12 2008-04-11 腎尿細管障害治療剤のスクリーニング方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-105067 2007-04-12
JP2007105067 2007-04-12
JP2007187486 2007-07-18
JP2007-187486 2007-07-18

Publications (1)

Publication Number Publication Date
WO2008133036A1 true WO2008133036A1 (fr) 2008-11-06

Family

ID=39925495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057148 WO2008133036A1 (fr) 2007-04-12 2008-04-11 Procédé de criblage d'un agent thérapeutique pour un dysfonctionnement tubulaire rénal

Country Status (2)

Country Link
JP (1) JPWO2008133036A1 (fr)
WO (1) WO2008133036A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072730A1 (fr) * 2000-03-28 2001-10-04 Michio Ishibashi Medicaments preventifs/remedes selectifs pour lesions evolutives apres endommagement d'un organe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072730A1 (fr) * 2000-03-28 2001-10-04 Michio Ishibashi Medicaments preventifs/remedes selectifs pour lesions evolutives apres endommagement d'un organe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORA ET AL.: "The rBAT Gene Is Responsible for L-Cystine Uptake via the b0, +-like Amino Acid Transport System in a "Renal Proximal Tubular" Cell Line (OK Cells)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 18, 1996, pages 10569 - 10576 *

Also Published As

Publication number Publication date
JPWO2008133036A1 (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2006119467A3 (fr) Modification d'activite de proteine
WO2007115305A3 (fr) Formes de dosage orales incluant un inhibiteur de l'agrégation plaquettaire et un inhibiteur acide
EP2036574A4 (fr) Préparation médicamenteuse destinée au traitement péroral de l'excès pondéral, du diabète sucré et de maladies accompagnées d'une perturbation de la tolérance du glucose
WO2006032134A3 (fr) Surveillance d'un traitement par radiotherapie au moyen d'ultrasons
WO2009105473A3 (fr) Procédés et dispositifs pour des soins de suivi et le traitement d'un pneumostome
EP2166928A4 (fr) Dispositif de surveillance médicale
MX2009007023A (es) Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2007117611A3 (fr) Expression augmentée de la superfamille des facteurs de nécrose tumorale et des arnm de chimiokines induite par le récepteur des lymphocytes t dans des leucocytes du sang périphérique chez des patients atteints de la maladie de crohn
EP2273918A4 (fr) Procedes, systemes et dispositifs de detection et de diagnostic de cardiopathies et de troubles cardiaques
EP2402752A3 (fr) Procédé de profilage pharmacologique de composés
EP1929946A4 (fr) Dispositif de détection des battements du c ur, de la respiration et du comportement d un petit animal
WO2010036960A8 (fr) Procédés pour traiter, diagnostiquer, et surveiller le lupus
EP1883446B8 (fr) Systeme de therapie implantable pour traiter un etre vivant avec un facteur actif
NO20081045L (no) Forbindelser og fremgangsmater for behandling av cancer
WO2008147483A3 (fr) Composés neurogéniques
EP2079518A4 (fr) Procédé, dispositif, stimulateur implantable et système pour thérapie cardiaque double chambre
WO2009043022A3 (fr) Traitements du cancer individualisés
TW200833688A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
IL200517A (en) Preparation for use in case of fructose intolerance
WO2009122444A3 (fr) Procédé pour le diagnostic d'un astrocytome de niveaux supérieur et inférieur à l'aide de biomarqueurs, et kit de diagnostic pour la mise en œuvre de ce procédé
WO2009022988A3 (fr) Vhz dans le diagnostic et le traitement du cancer
WO2008012692A3 (fr) Test d'efficacité des inhibiteurs d'histone déacétylase
WO2007118073A3 (fr) Obésité et distribution de graisse corporelle
UA93581C2 (ru) средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740245

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009511777

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740245

Country of ref document: EP

Kind code of ref document: A1